PomegraIovance Stock Jumps 31% After 2026 Guidance Raise
Why is Iovance stock up today?
Iovance Biotherapeutics (IOVA) stock jumped 31% to about $14.45 on Tuesday after the company raised its 2026 revenue guidance to $410–420 million, citing strong demand for its Amtagvi cancer therapy.
Key numbers
| 2026 revenue guidance | $410–420Mfrom $350–370M |
|---|---|
| IOVA share move | +31%to about $14.45 on Sep 29 |
| Q2 2026 product revenue | $99.3M+66% vs a year ago |
| Stock move this year | +425%year to date (per [2]) |
| Treatment centers | ~100targeting 110+ by year-end |
| Market value | $6.3Bafter the jump (per [3]) |
What happened
Iovance Biotherapeutics (IOVA) stock jumped 31% to about $14.45 on Tuesday after the company raised its 2026 revenue guidance to $410–420 million, citing strong demand for its Amtagvi cancer therapy. Guidance is a company's own forecast for the year. Iovance had expected $350–370 million, so the middle of the range rose by $55 million. The forecast follows a record second quarter, when product sales of $99.3 million were about 66% higher than a year earlier. The stock is up about 425% this year (per).
Why it matters
Iovance Biotherapeutics is showing that Amtagvi, a melanoma (skin cancer) treatment made from a patient's own immune cells, is selling faster than the company first planned. The new forecast implies sales growth of nearly 60% this year. That matters for a company still losing money: it reported a $47.3 million net loss in the second quarter. Goldman Sachs said early launch problems are starting to ease.
Who this affects
- MarketneutralLow impact
- Mostly a single-stock move; little effect on wider markets.
- CompanybullishHigh impact
- Stronger sales outlook boosts confidence in Amtagvi launch.
- CompetitorsneutralLow impact
- Cell-therapy peers face a stronger rival; effect unclear.
- IndustrybullishMedium impact
- Shows demand for personalized cancer cell therapies is building.
Iovance vs Legend Biotech, Autolus Therapeutics
How we got here
Iovance reports record Q2 product revenue of $99.3M and says it is reviewing guidance
Iovance raises 2026 revenue guidance to $410–420M; shares jump more than 30%
HC Wainwright lifts its price target on Iovance to $20 from $9 (per)
What to watch
- Third-quarter results, including Amtagvi sales compared with the raised full-year forecast2026-11
- Whether treatment centers reach at least 110 by year-end 20262026-12-31
Educational content only. Not investment advice.
More briefsAll briefs →
Russia Mobilization Grows as North Korea Preps 10,000 More Troops
Russia added 15,500 troops as strikes on Kyiv go on; 8,000 North Korean soldiers are already in Russia.
Financial Stocks Fall 6.3% in September as Treasury Yields Rise
Blackstone (BX) has slumped 21% and BlackRock (BLK) 8% as bond yields climb, hitting S&P 500 financials.
Bloom Energy Stock Jumps 10.8% on AI Power Orders
Bloom Energy (BE) closed at $291.25 as Jefferies lifted its target to $264, citing a $25B Brookfield deal.